Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes

Trial Profile

Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 03 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 05 Apr 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top